ArticleTherapeutic advances in psychopharmacology2018
When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity.
Article in Therapeutic advances in psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Impaired Speaking-Induced Suppression Predicts Degraded Agency and Hallucination Severity in Schizophrenia.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026Article
- Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia.Schizophrenia (Heidelberg, Germany) · 2024Article
- Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia.Behavioural brain research · 2023Article
- Treatment of Depression with Vortioxetine and Second Generation Antipsychotics During the Period of Remission Formation in Schizophrenia (Interim Data Analysis).Consortium psychiatricum · 2023Article
- Dual orexin/hypocretin receptor antagonism attenuates attentional impairments in an NMDA receptor hypofunction model of schizophrenia.bioRxiv : the preprint server for biology · 2023Article
- Abnormal resting-state functional connectivity underlies cognitive and clinical symptoms in patients with schizophrenia.Frontiers in human neuroscience · 2023Article
- Abnormal Information Flow in Schizophrenia Is Linked to Psychosis.Schizophrenia bulletin · 2022Article
- Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.International journal of molecular sciences · 2022Review
- Advantages and Limitations of Animal Schizophrenia Models.International journal of molecular sciences · 2022Review
- Vortioxetine as adjunctive therapy in the treatment of schizophrenia.Therapeutic advances in psychopharmacology · 2022Article
- The role of cognitive control in the positive symptoms of psychosis.NeuroImage. Clinical · 2022Article
- A Neural Biomarker for Hallucinations: Medial Prefrontal Aberrations in Neural Connectivity Predict Self-Agency Deficits and Hallucination Severity in Schizophrenia.Journal of brain research · 2021Article
- Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report.BMC pharmacology & toxicology · 2020Article
- Caregiver Burdens Associated With Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes, and Perceptions.Frontiers in psychiatry · 2019Article
- Examination of the Neural Basis of Psychoticlike Experiences in Adolescence During Reward Processing.JAMA psychiatry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Treatment-resistant schizophrenia is a serious clinical problem. We adopt a systems-level approach positing a greater role for cognitive control mechanisms in the development of psychotic symptoms and illustrate the clinical application of this
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.